Lv1
50 积分 2023-07-03 加入
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
2个月前
已完结
The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study
2个月前
已完结
KN046 shows tolerability and activity in TNBC
2个月前
已完结
Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody
3个月前
已完结
A comprehensive review of immune checkpoint inhibitors for cancer treatment
5个月前
已完结
CD19: a promising target for systemic sclerosis
5个月前
已完结
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
7个月前
已完结
Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer
7个月前
已完结
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
8个月前
已完结
Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study
8个月前
已完结
皖公网安备34019202002308
